<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36516126</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.</ArticleTitle><Pagination><StartPage>e0272104</StartPage><MedlinePgn>e0272104</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0272104</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0272104</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of corticospinal tract motor neurons. Previous studies showed that adenosine-mediated neuromodulation is disturbed in ALS and that vascular endothelial growth factor (VEGF) has a neuroprotective function in ALS mouse models. We evaluated how adenosine (A1R and A2AR) and VEGF (VEGFA, VEGFB, VEGFR-1 and VEGFR-2) system markers are altered in the cortex and spinal cord of pre-symptomatic and symptomatic SOD1G93A mice. We then assessed if/how chronic treatment of SOD1G93A mice with a widely consumed adenosine receptor antagonist, caffeine, modulates VEGF system and/or the levels of Brain-derived Neurotrophic Factor (BDNF), known to be under control of A2AR. We found out decreases in A1R and increases in A2AR levels even before disease onset. Concerning the VEGF system, we detected increases of VEGFB and VEGFR-2 levels in the spinal cord at pre-symptomatic stage, which reverses at the symptomatic stage, and decreases of VEGFA levels in the cortex, in very late disease states. Chronic treatment with caffeine rescued cortical A1R levels in SOD1G93A mice, bringing them to control levels, while rendering VEGF signaling nearly unaffected. In contrast, BDNF levels were significantly affected in SOD1G93A mice treated with caffeine, being decreased in the cortex and increased in spinal the cord. Altogether, these findings suggest an early dysfunction of the adenosinergic system in ALS and highlights the possibility that the negative influence of caffeine previously reported in ALS animal models results from interference with BDNF rather than with the VEGF signaling molecules.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Rei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rei</LastName><ForeName>N&#xe1;dia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0131-0126</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Cl&#xe1;udia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaz</LastName><ForeName>Sandra H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farinha-Ferreira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Joaquim A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebasti&#xe3;o</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#xea;ncias, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#xe3;o Lobo Antunes, Universidade de Lisboa, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018047">Receptors, Purinergic P1</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018047" MajorTopicYN="N">Receptors, Purinergic P1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36516126</ArticleId><ArticleId IdType="pmc">PMC9749988</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0272104</ArticleId><ArticleId IdType="pii">PONE-D-22-19570</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sebasti&#xe3;o AM, Rei N, and Ribeiro JA. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front. Pharmacol. 2018; 9:26. 10.3389/fphar.2018.00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00267</ArticleId><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, et al.. Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern. Med.1999; 38(2):133&#x2013;9. 213. doi: 10.2169/internalmedicine.38.133</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.38.133</ArticleId><ArticleId IdType="pubmed">10225668</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, et al.. A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2013; 14(5&#x2013;6):406&#x2013;13. doi: 10.3109/21678421.2013.793358</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.793358</ArticleId><ArticleId IdType="pubmed">23679925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SK, Higashimori H, Tolman M, and Yang Y. Suppression of adenosine 2a receptor (A2AR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2015; 267:115&#x2013;22. 10.1016/j.expneurol.2015.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.03.004</ArticleId><ArticleId IdType="pmc">PMC5363273</ArticleId><ArticleId IdType="pubmed">25779930</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JE, Chen HH, Winer J, Houck KA, and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem.1994; 269(41):25646&#x2013;54 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009; 89(2):607&#x2013;48. doi: 10.1152/physrev.00031.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00031.2008</ArticleId><ArticleId IdType="pubmed">19342615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp. Eye Res. 2006; 83(5):1005&#x2013;16. doi: 10.1016/j.exer.2006.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2006.03.019</ArticleId><ArticleId IdType="pmc">PMC1576298</ArticleId><ArticleId IdType="pubmed">16713597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, et al.. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J. Biol. Chem. 2002; 277(13):11410&#x2013;5. doi: 10.1074/jbc.M111085200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111085200</ArticleId><ArticleId IdType="pubmed">11777931</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, et al.. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J. Neurosci. 2008; 28(42):10451&#x2013;9. doi: 10.1523/JNEUROSCI.1092-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1092-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671326</ArticleId><ArticleId IdType="pubmed">18923022</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Hucha S, Pastor AM, Morcuende S. Neuroprotective Effect of Vascular Endothelial Growth Factor on Motoneurons of the Oculomotor System. Int J Mol Sci.2021; 22(2):814. doi: 10.3390/ijms22020814</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020814</ArticleId><ArticleId IdType="pmc">PMC7830098</ArticleId><ArticleId IdType="pubmed">33467517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn JS, Sakowski SA, Kim B, Rosenberg AA, and Feldman EL. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev. Neurobiol. 2009; 69(13):871&#x2013;84. 10.1002/dneu.20747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.20747</ArticleId><ArticleId IdType="pmc">PMC2853013</ArticleId><ArticleId IdType="pubmed">19672955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zheng L, Viera L, Suswam E, Li Y, Li X, et al.. Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J. Neurosci. 2007; 27(30):7929&#x2013;38. doi: 10.1523/JNEUROSCI.1877-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1877-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672720</ArticleId><ArticleId IdType="pubmed">17652584</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG, et al.. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2006; 65(1):26&#x2013;36. doi: 10.1097/01.jnen.0000196134.51217.74</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000196134.51217.74</ArticleId><ArticleId IdType="pubmed">16410746</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Storkebaum E, Vleminckx V, Moons L, Vanopdenbosch L, Scheveneels W, et al.. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 2004; 7(1):21&#x2013;8. doi: 10.1016/j.nbd.2004.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.06.004</ArticleId><ArticleId IdType="pubmed">15350962</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Ilieva H, Shiote M, Nagata T, Nagano I, Shoji M, et al.. Hypoxic induction of vascular endothelial growth factor is selectively impaired in mice carrying the mutant SOD1 gene. Brain Res. 2003; 989(2):231&#x2013;7. doi: 10.1016/s0006-8993(03)03374-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(03)03374-2</ArticleId><ArticleId IdType="pubmed">14556945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobile-Orazio E, Terenghi F, Giannotta C, Gallia F, and Nozza A. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology. 2009; 72(11):1024&#x2013;6. doi: 10.1212/01.wnl.0000344569.13496.ff</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000344569.13496.ff</ArticleId><ArticleId IdType="pubmed">19289745</ArticleId></ArticleIdList></Reference><Reference><Citation>Carilho R, de Carvalho M, Swash M, Pinto S, Pinto A, Costa J. Vascular endothelial growth factor and amyotrophic lateral sclerosis: the interplay with exercise and noninvasive ventilation. Muscle Nerve. 2014;49(4):545&#x2013;50. doi: 10.1002/mus.23955</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23955</ArticleId><ArticleId IdType="pubmed">23868282</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, et al.. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology. 2004; 62(11):2127&#x2013;9. doi: 10.1212/01.wnl.0000129913.44351.a3</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000129913.44351.a3</ArticleId><ArticleId IdType="pubmed">15184633</ArticleId></ArticleIdList></Reference><Reference><Citation>Just N, Moreau C, Lassalle P, Gosset P, Perez T, Brunaud-Danel V, et al.. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul. Disord. 2007; 17(2):169&#x2013;73. doi: 10.1016/j.nmd.2006.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2006.10.004</ArticleId><ArticleId IdType="pubmed">17142042</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Dest&#xe9;e A, et al.. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry. 2006; 77(2):255&#x2013;7. doi: 10.1136/jnnp.2005.070904</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.070904</ArticleId><ArticleId IdType="pmc">PMC2077591</ArticleId><ArticleId IdType="pubmed">16421133</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygren I, Larsson A, Johansson A, and Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport. 2022; 13(17):2199&#x2013;201. 10.1097/00001756-200212030-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200212030-00007</ArticleId><ArticleId IdType="pubmed">12488796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D, Poesen K, Fern&#xe1;ndez-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PWJ, et al.. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J. Med. Genet. 2009; 46(12):840&#x2013;6. doi: 10.1136/jmg.2008.058222</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2008.058222</ArticleId><ArticleId IdType="pubmed">18413368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PK, Prabhakar S, Sharma S, and Anand A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. J Neuroinflammation. 2011; 8:47. doi: 10.1186/1742-2094-8-47 Erratum in: J Neuroinflammation. 2011;8:97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-47</ArticleId><ArticleId IdType="pmc">PMC3117705</ArticleId><ArticleId IdType="pubmed">21569455</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Gomes C, and de Carvalho M. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol. Disord. Drug Targets. 2010; 9(6):764&#x2013;78 doi: 10.2174/187152710793237502</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710793237502</ArticleId><ArticleId IdType="pubmed">20942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, et al.. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005; 8(1):85&#x2013;92. doi: 10.1038/nn1360</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1360</ArticleId><ArticleId IdType="pubmed">15568021</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza RL, Armida M, Ferrante A, P&#xe8;zzola A, Matteucci A, Puopolo M. et al.. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2013; 1(4):585&#x2013;92. 10.1002/jnr.23185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23185</ArticleId><ArticleId IdType="pubmed">23361938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o AM, and Ribeiro JA. Adenosine receptors and the central nervous system. Handb. Exp. Pharmacol. 2009; (193):471&#x2013;534. doi: 10.1007/978-3-540-89615-9_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-89615-9_16</ArticleId><ArticleId IdType="pubmed">19639292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernens I, L&#xe9;onard F, Vausort M, Rolland-Turner M, Devaux Y, and Wagner DR. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem. Biophys. Res. Commun. 2010; 392(3):351&#x2013;6. 10.1016/j.bbrc.2010.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.01.023</ArticleId><ArticleId IdType="pubmed">20067761</ArticleId></ArticleIdList></Reference><Reference><Citation>Rei N, Rombo DM, Ferreira MF, Baqi Y, M&#xfc;ller CE, Ribeiro JA, et al.. Hippocampal synaptic dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis: reversal by adenosine A2AR blockade. Neuropharmacology. 2020; 171:108106. 10.1016/j.neuropharm.2020.108106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.108106</ArticleId><ArticleId IdType="pubmed">32311420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento F, Pousinha PA, Correia AM, Gomes R, Sebasti&#xe3;o AM, Ribeiro JA. Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre- symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase. PLoS One. 2014; 9(8):e104081. doi: 10.1371/journal.pone.0104081</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104081</ArticleId><ArticleId IdType="pmc">PMC4122437</ArticleId><ArticleId IdType="pubmed">25093813</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento F, Sebasti&#xe3;o AM, and Ribeiro JA. Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal. 2015; 11(4):471&#x2013;80. doi: 10.1007/s11302-015-9465-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-015-9465-4</ArticleId><ArticleId IdType="pmc">PMC4648802</ArticleId><ArticleId IdType="pubmed">26335190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. doi: 10.1093/nar/29.9.e45</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/29.9.e45</ArticleId><ArticleId IdType="pmc">PMC55695</ArticleId><ArticleId IdType="pubmed">11328886</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga D, Meulia T, and Fenster S. Real-Time PCR. Curr. Protoc. Essent. Lab. Tech. 2008; 00, 10.3.1&#x2013;10.3.34. 10.1002/9780470089941.et1003s00.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470089941.et1003s00</ArticleId></ArticleIdList></Reference><Reference><Citation>Batalha VL, Pego JM, Fontinha BM, Costenla AR, Valadas JS, Baqi Y, et al.. Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol. Psychiatry. 2013; 18(3):320&#x2013;31. 10.1038/mp.2012.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.8</ArticleId><ArticleId IdType="pubmed">22371048</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong LAA, Uges DRA, Franke JP, and Bischoff R. Receptor&#x2013;ligand binding assays: Technologies and Applications. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 829(1&#x2013;2):1&#x2013;25. doi: 10.1016/j.jchromb.2005.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2005.10.002</ArticleId><ArticleId IdType="pubmed">16253574</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Louren&#xe7;o C, Duarte ST, Palminha C, Gaspar C, Rodrigues TM, Magalh&#xe3;es-Cardoso T, et al.. Impairment of adenosinergic system in Rett syndrome: Novel therapeutic target to boost BDNF signalling. Neurobiol Dis. 2020;145:105043. doi: 10.1016/j.nbd.2020.105043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105043</ArticleId><ArticleId IdType="pubmed">32798727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa VC, Assaife-Lopes N, Ribeiro JA, Pratt JA, Brett RR, Sebasti&#xe3;o AM. Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of &#x394;9-tetrahydrocannabinol on spatial memory. Neuropsychopharmacology. 2011; 36(2):472&#x2013;87. 10.1038/npp.2010.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2010.179</ArticleId><ArticleId IdType="pmc">PMC3055664</ArticleId><ArticleId IdType="pubmed">20927050</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett LW, Fletcher S, and Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell. Mol. Life Sci. 2012; 69, 3613&#x2013;3634. doi: 10.1007/s00018-012-0990-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-0990-9</ArticleId><ArticleId IdType="pmc">PMC3474909</ArticleId><ArticleId IdType="pubmed">22538991</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier T, G&#xfc;ell M, and Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009; 583(24):3966&#x2013;73. 10.1016/j.febslet.2009.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.10.036</ArticleId><ArticleId IdType="pubmed">19850042</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus J, Cheng Z, and Vogel C. Next-generation analysis of gene expression regulation- -comparing the roles of synthesis and degradation. Mol. Biosyst. 2015; 11(10):2680&#x2013;9. doi: 10.1039/c5mb00310e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c5mb00310e</ArticleId><ArticleId IdType="pmc">PMC4573910</ArticleId><ArticleId IdType="pubmed">26259698</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillis JW, Edstrom JP, Kostopoulos GK, &amp; Kirkpatrick JR. Effects of adenosine and adenine nucleotides on synaptic transmission in the cerebral cortex. Can J Physiol Pharmacol. 1979; 57(11):1289&#x2013;312. doi: 10.1139/y79-194</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y79-194</ArticleId><ArticleId IdType="pubmed">93018</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi M, Raiteri L, Risso F, Vallarino A, Bonfanti A, Monopoli A, et al.. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol. 2002; 136(3):434&#x2013;40. Erratum in: Br J Pharmacol. 2002 Sep;137(2):294. doi: 10.1038/sj.bjp.0704712</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0704712</ArticleId><ArticleId IdType="pmc">PMC1573357</ArticleId><ArticleId IdType="pubmed">12023946</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MK, Pinnock RD, and Lee K. Adenosine exerts multiple effects in dorsal horn neurones of the adult rat spinal cord. Brain Res. 2001; 20(1&#x2013;2):19&#x2013;26. doi: 10.1016/s0006-8993(01)02844-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(01)02844-x</ArticleId><ArticleId IdType="pubmed">11716807</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Eisenach JC. Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology. 2005;103(5):1060&#x2013;5. doi: 10.1097/00000542-200511000-00021</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200511000-00021</ArticleId><ArticleId IdType="pubmed">16249681</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Lubitz DK, Lin RC, Melman N, Ji XD, Carter MF, Jacobson KA. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol. 1994; 256(2):161&#x2013;7. doi: 10.1016/0014-2999(94)90241-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(94)90241-0</ArticleId><ArticleId IdType="pmc">PMC5553070</ArticleId><ArticleId IdType="pubmed">8050467</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 1996;17(3):108&#x2013;13. doi: 10.1016/0165-6147(96)10002-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-6147(96)10002-x</ArticleId><ArticleId IdType="pmc">PMC3431161</ArticleId><ArticleId IdType="pubmed">8936347</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mendon&#xe7;a A, Sebasti&#xe3;o AM, Ribeiro JA. Adenosine: does it have a neuroprotective role after all? Brain Res Brain Res Rev. 2000;33(2&#x2013;3):258&#x2013;74. doi: 10.1016/s0165-0173(00)00033-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-0173(00)00033-3</ArticleId><ArticleId IdType="pubmed">11011069</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson T, Cronberg T, Rytter A, Aszt&#xe9;ly F, Fredholm BB, Smith ML et al.. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. Eur J Neurosci. 2004;20(5):1197&#x2013;204. doi: 10.1111/j.1460-9568.2004.03564.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03564.x</ArticleId><ArticleId IdType="pubmed">15341591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha RA. Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal. 2005; 1(2):111&#x2013;34. doi: 10.1007/s11302-005-0649-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-005-0649-1</ArticleId><ArticleId IdType="pmc">PMC2096528</ArticleId><ArticleId IdType="pubmed">18404497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro FF, Xapelli S, Miranda-Louren&#xe7;o C, Tanqueiro SR, Fonseca-Gomes J, Di&#xf3;genes MJ,et al.. Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology. 2016; 104:226&#x2013;42. doi: 10.1016/j.neuropharm.2015.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.11.006</ArticleId><ArticleId IdType="pubmed">26577017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha RA, Constantino MC, Sebasti&#xe3;o AM, Ribeiro JA. Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport. 1995; 6(11):1583&#x2013;8. doi: 10.1097/00001756-199507310-00029</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199507310-00029</ArticleId><ArticleId IdType="pubmed">7579154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o AM, Cunha RA, de Mendon&#xe7;a A, Ribeiro JA. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. Br J Pharmacol. 2000;131(8):1629&#x2013;34. doi: 10.1038/sj.bjp.0703736</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0703736</ArticleId><ArticleId IdType="pmc">PMC1572495</ArticleId><ArticleId IdType="pubmed">11139440</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho JE, Rebola N, Fragata I, Ribeiro JA, de Mendon&#xe7;a A, Cunha RA. Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus. Neuroscience. 2006;138(4):1195&#x2013;203. doi: 10.1016/j.neuroscience.2005.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2005.12.012</ArticleId><ArticleId IdType="pubmed">16442739</ArticleId></ArticleIdList></Reference><Reference><Citation>Armida M, Matteucci A, P&#xe8;zzola A, Baqi Y, M&#xfc;ller CE, Popoli P, et al.. Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93 A Mutant Mice. Neurochem Res. 2019;44(5):1037&#x2013;1042. 10.1007/s11064-019-02745-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-019-02745-0</ArticleId><ArticleId IdType="pubmed">30756215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanpallewar SU, Barrick CA, Buckley H, Becker J, Tessarollo L. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012; 7(6): e39946. doi: 10.1371/journal.pone.0039946</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039946</ArticleId><ArticleId IdType="pmc">PMC3384607</ArticleId><ArticleId IdType="pubmed">22761934</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008; 131(Pt 6):1540&#x2013;50. Erratum in: Brain. 2008 Aug;131(Pt 8):2234. doi: 10.1093/brain/awn071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn071</ArticleId><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2018; 31(5):640&#x2013;647. doi: 10.1097/WCO.0000000000000593</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000593</ArticleId><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, et al.. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001;77(2):383&#x2013;90. doi: 10.1046/j.1471-4159.2001.00188.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00188.x</ArticleId><ArticleId IdType="pubmed">11299300</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander MD, Traynor BJ, Miller N, Corr B, Frost E, McQuaid S, Brett FM, et al.. "True" sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol. 2002;52(5):680&#x2013;3. doi: 10.1002/ana.10369</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10369</ArticleId><ArticleId IdType="pubmed">12402272</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Geracitano R, Berretta N, Sgobio C, Bernardi G, Mercuri NB, et al.. Molecular and synaptic changes in the hippocampus underlying superior spatial abilities in pre-symptomatic G93A+/+ mice overexpressing the human Cu/Zn superoxide dismutase (Gly93 &#x2014;&gt; ALA) mutation. Exp Neurol. 2006; 197(2):505&#x2013;14. 10.1016/j.expneurol.2005.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.10.014</ArticleId><ArticleId IdType="pubmed">16309674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha MC, Pousinha PA, Correia AM, Sebasti&#xe3;o AM, Ribeiro JA. Early changes of neuromuscular transmission in the SOD1(G93A) mice model of ALS start long before motor symptoms onset. PLoS One. 2013; 8(9):e73846. doi: 10.1371/journal.pone.0073846</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073846</ArticleId><ArticleId IdType="pmc">PMC3764017</ArticleId><ArticleId IdType="pubmed">24040091</ArticleId></ArticleIdList></Reference><Reference><Citation>Pousinha PA, Diogenes MJ, Ribeiro JA, Sebasti&#xe3;o AM. Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci Lett. 2006; 404(1&#x2013;2):143&#x2013;7. 10.1016/j.neulet.2006.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.05.036</ArticleId><ArticleId IdType="pubmed">16790314</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges-Martins VPP, Ferreira DDP, Souto AC, Oliveira Neto JG, Pereira-Figueiredo D, da Costa Calaza K, et al.. Caffeine regulates GABA transport via A1R blockade and cAMP signaling. Neurochem Int. 2019; 131:104550. doi: 10.1016/j.neuint.2019.104550</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.104550</ArticleId><ArticleId IdType="pubmed">31563462</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunwiddie TV, and Masino SA. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 2001; 24: 31&#x2013;55. doi: 10.1146/annurev.neuro.24.1.31</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.31</ArticleId><ArticleId IdType="pubmed">11283304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaelin-Lang A, Lauterburg T, and Burgunder JM. Expression of adenosine A2a receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci. Lett. 1999; 261(3):189&#x2013;91. doi: 10.1016/s0304-3940(99)00022-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(99)00022-1</ArticleId><ArticleId IdType="pubmed">10081981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredholm BB, B&#xe4;ttig K, Holm&#xe9;n J, Nehlig A, and Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999; 51(1):83&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro JA, and Sebasti&#xe3;o AM. Caffeine and adenosine. J Alzheimers Dis. 2010; 20 Suppl 1:S3&#x2013;15. doi: 10.3233/JAD-2010-1379</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1379</ArticleId><ArticleId IdType="pubmed">20164566</ArticleId></ArticleIdList></Reference><Reference><Citation>Boia R, Elvas F, Madeira MH, Aires ID, Rodrigues-Neves AC, Tralh&#xe3;o P, et al.. Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage. Cell death &amp; disease. 2017; 8(10), e3065. doi: 10.1038/cddis.2017.451</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.451</ArticleId><ArticleId IdType="pmc">PMC5680573</ArticleId><ArticleId IdType="pubmed">28981089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha RA. How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem. 2016; 139(6):1019&#x2013;1055. doi: 10.1111/jnc.13724</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13724</ArticleId><ArticleId IdType="pubmed">27365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo PM, de la Cruz RR, Pastor AM. Synaptic loss and firing alterations in Axotomized Motoneurons are restored by vascular endothelial growth factor (VEGF) and VEGF-B. Exp Neurol. 2018; 304:67&#x2013;81. doi: 10.1016/j.expneurol.2018.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.03.004</ArticleId><ArticleId IdType="pubmed">29522757</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan J, Noakes PG, Bellingham MC. The Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis. Front Cell Neurosci. 2019; 13:368. 10.3389/fncel.2019.00368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00368</ArticleId><ArticleId IdType="pmc">PMC6700252</ArticleId><ArticleId IdType="pubmed">31456666</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanpallewar S, Fulgenzi G, Tomassoni-Ardori F, Barrick C, Tessarollo L. Delayed onset of inherited ALS by deletion of the BDNF receptor TrkB.T1 is non-cell autonomous. Exp Neurol. 2021; 337:113576. doi: 10.1016/j.expneurol.2020.113576</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113576</ArticleId><ArticleId IdType="pmc">PMC9229840</ArticleId><ArticleId IdType="pubmed">33359475</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontinha BM, Di&#xf3;genes MJ, Ribeiro JA, Sebasti&#xe3;o AM. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology. 2008; 54(6):924&#x2013;33. 10.1016/j.neuropharm.2008.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.01.011</ArticleId><ArticleId IdType="pubmed">18384819</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#xf3;genes MJ, Costenla AR, Lopes LV, Jer&#xf3;nimo-Santos A, Sousa VC, Fontinha BM, et al.. Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology. 2011;36(9):1823&#x2013;36. doi: 10.1038/npp.2011.64</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2011.64</ArticleId><ArticleId IdType="pmc">PMC3154100</ArticleId><ArticleId IdType="pubmed">21525862</ArticleId></ArticleIdList></Reference><Reference><Citation>Jer&#xf3;nimo-Santos A, Batalha VL, M&#xfc;ller CE, Baqi Y, Sebasti&#xe3;o AM, Lopes LV, et al.. Impact of in vivo chronic blockade of adenosine A2A receptors on the BDNF-mediated facilitation of LTP. Neuropharmacology. 2014; 83:99&#x2013;106. 10.1016/j.neuropharm.2014.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.04.006</ArticleId><ArticleId IdType="pubmed">24747180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei CJ, Augusto E, Gomes CA, Singer P, Wang Y, Boison D, et al.. Regulation of fear responses by striatal and extrastriatal adenosine A2A receptors in forebrain. Biol Psychiatry. 2014;75(11):855&#x2013;63. doi: 10.1016/j.biopsych.2013.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2013.05.003</ArticleId><ArticleId IdType="pmc">PMC4058554</ArticleId><ArticleId IdType="pubmed">23820821</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Tsuda M. Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors. Biochem Pharmacol. 2021;187:114309. doi: 10.1016/j.bcp.2020.114309</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114309</ArticleId><ArticleId IdType="pubmed">33130129</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, et al.. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun. 2011;25(5):1025&#x2013;35. doi: 10.1016/j.bbi.2010.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Amadio S, Napoli G, Freschi M, Sironi F, et al.. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model. Int J Mol Sci. 2021. Sep 30;22(19):10649. doi: 10.3390/ijms221910649</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910649</ArticleId><ArticleId IdType="pmc">PMC8508678</ArticleId><ArticleId IdType="pubmed">34638992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, et al.. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol. 2007; 83(5):310&#x2013;31. doi: 10.1016/j.pneurobio.2007.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2007.09.002</ArticleId><ArticleId IdType="pubmed">18023959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai SS, Zhou YG. Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev Neurosci. 2011;22(2):231&#x2013;9. doi: 10.1515/RNS.2011.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/RNS.2011.020</ArticleId><ArticleId IdType="pubmed">21476942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kume T, Kouchiyama H, Kaneko S, Maeda T, Kaneko S, Akaike A, et al.. BDNF prevents NO mediated glutamate cytotoxicity in cultured cortical neurons. Brain Res. 1997; 756(1&#x2013;2):200&#x2013;4. doi: 10.1016/s0006-8993(97)00195-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(97)00195-9</ArticleId><ArticleId IdType="pubmed">9187333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem. 1999; 274(32):22569&#x2013;80. doi: 10.1074/jbc.274.32.22569</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.32.22569</ArticleId><ArticleId IdType="pubmed">10428835</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiva I, Cellai L, Meriaux C, Poncelet L, Nebie O, Saliou JM, et al.. Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription. J Clin Invest. 2022. Jun 15;132(12):e149371. doi: 10.1172/JCI149371</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149371</ArticleId><ArticleId IdType="pmc">PMC9197525</ArticleId><ArticleId IdType="pubmed">35536645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>